Somapacitan

From WikiMD's WELLNESSPEDIA

(Redirected from Sogroya)

Somapacitan is a drug used for the treatment of growth hormone deficiency in adults. It is a growth hormone analog that is administered once weekly, and it works by stimulating growth and cell reproduction in the body.

Mechanism of Action[edit]

Somapacitan works by binding to the growth hormone receptor on the surface of cells. This binding triggers a series of reactions within the cell that lead to the growth and reproduction of cells.

Uses[edit]

Somapacitan is used to treat adults with growth hormone deficiency. This condition can cause a variety of symptoms, including decreased muscle mass, increased body fat, and decreased bone density. By providing a steady supply of growth hormone, somapacitan can help to alleviate these symptoms.

Side Effects[edit]

Like all drugs, somapacitan can cause side effects. The most common side effects include injection site reactions, muscle pain, joint pain, and headache. In rare cases, somapacitan can cause more serious side effects, such as high blood sugar levels or an allergic reaction.

History[edit]

Somapacitan was developed by the Danish pharmaceutical company Novo Nordisk. It was approved for use in the European Union in 2020, and in the United States in 2021.

See Also[edit]


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.